Info

Peregrine Pharmaceuticals, Inc. (Peregrine) is a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection. The Company is advancing three separate clinical programs with its compounds bavituximab and Cotara that employ its two platform technologies: Anti-Phosphatidylserine (Anti-PS) therapeutics and Tumor Necrosis Therapy (TNT). Peregrine’s Anti-PS product, bavituximab, is being studied in two separate clinical trial programs for the treatment of various solid tumors and HCV infection. The Company has completed a Phase Ib cancer trial assessing the safety and anti-tumor activity of bavituximab administered in combination with chemotherapy in patients with solid cancers. Data gathered from that Phase Ib study was utilized in the design of three separate Phase II trials of bavituximab in combination with chemotherapy for the treatment of solid tumors.(Source: 10-K)